Printer Friendly

SCIOS REPORTS FIRST QUARTER 1992 FINANCIAL RESULTS

 SCIOS REPORTS FIRST QUARTER 1992 FINANCIAL RESULTS
 MOUNTAIN VIEW, Calif., April 22 /PRNewswire/ -- Scios Inc.


(NASDAQ: SCIO) (formerly California Biotechnology Inc.) today announced financial results for the first quarter ended March 31, 1992.
 Scios reported a net loss of $3,409,000 (19 cents per share) for the first quarter ended March 31, 1992, compared to a net loss of $2,113,000 (18 cents per share) in the same period last year.
 For the first quarter 1992, Scios reported revenues of $1,634,000 and costs and expenses of $6,939,000. In the similar period last year, Scios reported revenues of $2,206,000 and costs and expenses of $5,150,000. Research contract revenues to Scios under its collaboration with Pfizer have been reduced compared to last year as insulinotropin has advanced to later stages of development performed directly by Pfizer Inc. The rise in costs and expenses in 1992 reflects Scios' increased efforts in product development and a significant expansion of its medical and regulatory staff. In addition, Scios has undertaken a variety of activities in anticipation of bringing products to market including the company's recently announced name change.
 Scios also reported investment and other income of $1,896,000 for the first quarter 1992, compared to $837,000 in the similar period last year. The increase resulted from interest received in connection with the investment of the proceeds from the secondary public offerings completed during 1991. At quarter-end, Scios had approximately $122 million in cash and marketable securities.
 "Our expenses for the first quarter, which are in line which expectations, reflect an increase in the intensity of our product development programs over last year," commented Richard L. Casey, Scios' president and chief executive officer. "On an organizational level, we have now established a core group of medical and regulatory staff to meet the increasing needs of our clinical trials. With this key group in place, we will also be well-positioned when early-stage products in the pipeline emerge from preclinical testing."
 Scios has three products in Phase II clinical trials, one in each of its focus areas: cardiopulmonary disease, tissue repair, and metabolic disorders. In the metabolic area, Phase II trials with insulinotropin for treatment of Type II diabetes progressed under the direction of Pfizer. The first publication of human clinical data for insulinotropin in the first quarter highlights its promise as a treatment for Type II diabetes.
 In the February 1992 issue of the journal Diabetes Care, researchers at Massachusetts General Hospital reported that insulinotropin appears to safely and effectively regulate blood sugar levels in Type II diabetics. While this study is preliminary, the findings suggest that insulinotropin may have a key potential benefit over current therapies. When administered after a meal, insulinotropin appears to more closely mimic the natural regulation of blood sugar, reducing insulin release as glucose levels fall, thereby avoiding hypoglycemia.
 The MGH insulinotropin study, performed for research purposes, is independent of the company's ongoing clinical development program with Pfizer. Scios acquired an exclusive license from MGH in 1988 for the commercial development of insulinotropin.
 In the cardiopulmonary area, Auriculin(R) atrial natriuretic peptide is undergoing evaluation for two kidney disorders: radiocontrast induced nephropathy (RCIN) and acute renal failure. Clinical trials for these indications are advancing to determine the optimal route of administration for pivotal Phase III trials which are expected to begin in 1992.
 Fibroblast growth factor (FGF), the lead agent in Scios' tissue repair program, is in Phase II clinical trials for soft tissue ulcers in the United States and in Japan through Scios' commercial partner for the Asian market, Kaken Pharmaceutical Co., Ltd. E. Merck, a major German pharmaceutical company and Scios' partner for European territories, has advanced FGF to the late stages of preclinical development for soft tissue wounds and bone repair.
 Scios is conducting preclinical studies with five additional products including brain natriuretic peptide (BNP) as a treatment for certain cardiovascular diseases; and heparin binding epidermal growth factor-like growth factor (HB-EGF), a new tissue repair factor which may be useful for gastrointestinal and lung disorders.
 Scios Inc. (formerly California Biotechnology Inc.) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios focuses its efforts in three areas -- cardiopulmonary disease, tissue repair, and metabolic disorders. The company develops and commercializes products on a proprietary basis and in collaboration with established companies.
 SCIOS INC. AND SUBSIDIARIES
 Consolidated Balance Sheets
 (In thousands, except share data)
 3/31/92 12/31/91
 (Unaudited)
 ASSETS
 Current assets:
 Cash and cash equivalents $ 26,450 $ 29,825
 Marketable securities 59,238 64,946
 Contract revenues receivable 1,754 677
 Other receivables 2,130 1,979
 Prepaid expenses 898 870
 Total current assets 90,470 98,297
 Non-current marketable securities 36,633 31,909
 Property and equipment, net 31,584 30,596
 Other assets 49 170
 Total assets 158,736 160,972
 LIABILITIES AND STOCKHOLDERS' EQUITY
 Current liabilities:
 Accounts payable $ 2,730 $ 2,309
 Accrued payroll 786 1,182
 Deferred contract revenue 792 501
 Other current liabilities 1,177 888
 Total current liabilities 5,485 4,880
 Stockholders' equity:
 Common stock, $.01 par value; issued
 and outstanding: 18,400,488 and
 18,322,847, respectively 184 183
 Additional paid-in capital 222,996 222,429
 Accumulated deficit (69,929) (66,520)
 Total stockholders' equity 153,251 156,092
 Total liabilities and stockholders'
 equity 158,736 160,972
 SCIOS INC. AND SUBSIDIARIES
 Consolidated Statements of Operations
 (In thousands, except share data)
 (Unaudited)
 Three Months Ended March 31 1992 1991
 Revenues:
 Research & development contracts $1,634 $2,206
 License income -- --
 Total 1,634 2,206
 Costs and expenses:
 Research and development 4,831 3,767
 General and administrative 2,108 1,383
 Total 6,939 5,150
 Loss from operations (5,305) (2,944)
 Other income:
 Investment income 1,758 715
 Other income, net 138 122
 Total 1,896 837
 Minority interests -- (6)
 Net loss (3,409) (2,113)
 Net loss per share $(0.19) $(0.18)
 Weighted average number of shares
 outstanding 18,365,679 11,954,742
 -0- 4/22/92
 /CONTACT: Virginia Walker of Scios, 415-940-6631 or 415-966-1550, or Robert Gottlieb of Feinstein Partners, 617-577-8110, for Scios/
 (SCIO) CO: Scios Inc. ST: California IN: MTC SU: ERN


GK-PS -- NY012 -- 1041 04/22/92 08:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1992
Words:1047
Previous Article:NORTH ATLANTIC INDUSTRIES REPORTS NINTH CONSECUTIVE RECORD QUARTERLY RESULTS
Next Article:VERTEX PHARMACEUTICALS REPORTS 1992 FIRST QUARTER RESULTS


Related Articles
NOVA PHARMACEUTICAL REPORTS SECOND QUARTER RESULTS
SCIOS INC. REPORTS SECOND QUARTER AND SIX-MONTH 1992 FINANCIAL RESULTS
SCIOS NOVA REPORTS THIRD QUARTER AND NINE-MONTH 1992 FINANCIAL RESULTS
SCIOS NOVA EXERCISES OPTION TO PURCHASE INTERESTS IN NOVA TECHNOLOGY LIMITED PARTNERSHIP
SCIOS NOVA ANNOUNCES 1993 FIRST QUARTER FINANCIAL RESULTS
SCIOS NOVA ANNOUNCES 1993 SECOND QUARTER AND SIX-MONTH FINANCIAL RESULTS
SCIOS NOVA ANNOUNCES 1993 YEAR-END AND FOURTH QUARTER FINANCIAL RESULTS
SCIOS NOVA ANNOUNCES 1994 FIRST QUARTER FINANCIAL RESULTS
Scios Announces First Quarter Financial Results.
Scios Reports First Quarter 2001 Financial Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters